|Systematic (IUPAC) name|
|Biological half-life||3-5 hours|
|Molecular mass||246.305 g/mol|
|(what is this?)|
Nefiracetam's cytoprotective actions are mediated by enhancement of GABAergic, cholinergic, and monoaminergic neuronal systems. It has been shown to effectively treat apathy and improve motivation in post-stroke patients. It has been shown to exhibit antiamnesia effects for the Alzheimer's type and cerebrovascular type of dementia. In addition, it has also been shown to have antiamnesia effects against a wide variety of memory impairing substances, including: ethanol, chlorodiazepoxide (Librium), scopolamine, bicuculline, picrotoxin, and cycloheximide.
Studies of long term consumption of nefiracetam in humans and primates have shown it to have no toxicity. However, animals which metabolize nefiracetam differently from humans and primates are at risk for renal and testicular toxicity. Dogs especially are particularly sensitive, which has been shown to be caused by a specific metabolite, M-18. Higher doses than those in dogs were needed to cause testicular toxicity in rats, although no toxicity was seen in monkeys. Additionally, there has been no evidence of toxicity during clinical trials.
- Fujimaki Y, Sudo K, Hakusui H, Tachizawa H, Murasaki M (September 1992). "Single- and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers". The Journal of Pharmacy and Pharmacology 44 (9): 750–4. doi:10.1111/j.2042-7158.1992.tb05513.x. PMID 1360528.
- Murphy, Keith J; Foley, Andrew G; O'Connell, Alan W; Regan, Ciaran M (29 June 2005). "Chronic Exposure of Rats to Cognition Enhancing Drugs Produces a Neuroplastic Response Identical to that Obtained by Complex Environment Rearing". Neuropsychopharmacology 31: 90–100. doi:10.1038/sj.npp.1300810. PMID 15988469.
- Robinson RG, Jorge RE, Clarence-Smith K, Starkstein S (2009). "Double-blind treatment of apathy in patients with poststroke depression using nefiracetam". The Journal of Neuropsychiatry and Clinical Neurosciences 21 (2): 144–51. doi:10.1176/appi.neuropsych.21.2.144. PMID 19622685.
- Robinson RG, Jorge RE, Clarence-Smith K (2008). "Double-blind randomized treatment of poststroke depression using nefiracetam". The Journal of Neuropsychiatry and Clinical Neurosciences 20 (2): 178–84. doi:10.1176/appi.neuropsych.20.2.178. PMID 18451188.
- Hiramatsu M, Shiotani T, Kameyama T, Nabeshima T. (Feb 1997). "Effects of nefiracetam on amnesia animal models with neuronal dysfunctions". Behavioural Brain Research 83 (1-2): 107–115. doi:10.1016/s0166-4328(97)86053-6.
- M Murasaki, M Inami, J Ishigooka, H Watanabe, M Utsumi, T Matsumoto; et al. (1994). "Phase I study on DM-9384 (nefiracetam)". Jpn. Pharmacol. Ther. 22: 3539–3587.
- E Otomo, K Kogure, S Hirai, F Goto, K Hasegawa, Y Tazaki; et al. (1994). "Clinical evaluation of DM-9384 in the treatment of cerebrovascular disorders: early phase II study". Jpn. Pharmacol. Ther. (22): 3589–3624.
- Shimada, M; Shikanai, Y; Shimomura, K; Harada, S; Watanabe, G; Taya, K; Kato, M; Furuhama, K (2003). "Investigation of testicular toxicity of nefiracetam, a neurotransmission enhancer, in rats". Toxicology letters 143 (3): 307–15. doi:10.1016/s0378-4274(03)00197-8. PMID 12849691.
- Shimomura, K; Shimada, M; Hagiwara, M; Harada, S; Kato, M; Furuhama, K (2004). "Testicular toxicity induced in dogs by nefiracetam, a neutrotransmission enhancer". Reproductive toxicology (Elmsford, N.Y.) 18 (3): 423–30. doi:10.1016/j.reprotox.2004.01.008. PMID 15082078.
- Goto, Koichi; Ishii, Yoshikazu; Jindo, Toshimasa; Furuhama, Kazuhisa (3 March 2003). "Effect of Nefiracetam, a Neurotransmission Enhancer, on Primary Uroepithelial Cells of the Canine Urinary Bladder". Toxicological Sciences 1 (72): 164–70. doi:10.1093/toxsci/kfg010. PMID 12604846.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|